Xian Zeng

Company: Byterna Therapeutics

Job title: Chief Executive Officer & Co-Founder

Seminars:

Scarless Circular mRNA In Vivo CAR-T Exhibits Potent Pharmacological Efficacy in Preclinical Models 3:30 pm

CellectLNP is a versatile platform for modular engineering of antibody-conjugated LNPs to achieve efficient and selective in vivo CAR cmRNA delivery to T cells cmCAR, a prolonged and enhanced CAR expression platform enabled by scarless circular mRNA technology, exhibits superior efficiency for in vivo engineering of CAR-T cells Robust anti-cancer activity and profound B cell-depletion…Read more

day: Day Two